A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl  by Kimura, Tatsuya et al.
A non-peptide compound which can mimic the e¡ect of thrombopoietin
via c-Mpl
Tatsuya Kimura*, Hiroshi Kaburaki, Tomomi Tsujino, Yoshitaka Ikeda, Hideo Kato,
Yoshinari Watanabe
Research and Development Division, Hokuriku Seiyaku Co., Ltd., Inokuchi, Katsuyama, Fukui 911-8555, Japan
Received 21 April 1998
Abstract Thrombopoietin (TPO) is a cytokine which plays a
central role in megakaryopoiesis and platelet production by
binding to its cell surface receptor, termed c-Mpl. In the present
study, two benzodiazepinones that compete with the binding of
TPO to the extracellular region of c-Mpl were identified, and
one of them stimulated the proliferation of a human TPO-
dependent megakaryocytic cell line, UT-7/TPO. It stimulated
the activation of signal transducer and activator of transcription
5 in UT-7/TPO cells. These results suggest that a non-peptide
compound can mimic the effect of TPO via c-Mpl.
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1. Introduction
Thrombopoietin (TPO) is a cytokine which has biological
e¡ects as a major mediator of megakaryocyte growth and
platelet production [1^8]. TPO supports the proliferation of
megakaryocyte progenitors and induces their di¡erentiation
into mature megakaryocytes. TPO exerts its action by binding
to a speci¢c cell surface receptor encoded by c-mpl [1^5]. c-
Mpl is a member of the cytokine receptor superfamily [9].
The binding of a cytokine to its speci¢c receptor on the cell
surface induces tyrosine phosphorylations and activation of
several proteins, including a receptor itself, receptor-associ-
ated tyrosine kinases such as Janus kinases (JAKs) and signal
transducers and activators of transcriptions (STATs) [10^15].
Activated STATs then form dimers, translocate into the nu-
cleus, and bind to a speci¢c DNA sequence and modulate
transcription [10^15]. TPO induces the tyrosine phosphoryla-
tion of JAK2 and TYK2 and the activation of STAT1,
STAT3 and STAT5 in several cell lines, including mouse
megakaryocytes and human platelets [16^27].
For several years, random phage peptide libraries have been
used to identify novel agonist peptides for erythropoietin
(EPO) receptor [28]. Recently we and Cwirla et al. independ-
ently detected novel agonist peptides for c-Mpl [29,30]. These
reports were the ¢rst proof that small peptides could exhibit
bioactivity of a large polypeptide hormone through its recep-
tor. There is no report that a non-peptide compound can do
so, to our knowledge.
The human leukemia cell line UT-7 was established from
the bone marrow cells of a patient with acute megakaryoblas-
tic leukemia [31]. UT-7/GM, a subline of UT-7, can prolifer-
ate in response to granulocyte-macrophage colony stimulating
factor (GM-CSF) or TPO [32,33]. The subline UT-7TPO was
established from UT-7/GM by culture at lower concentrations
of TPO and had morphologically mature megakaryocytic
characteristics [33].
In the present study, we identi¢ed two benzodiazepinones
that compete with the binding of TPO to human immunoglo-
bulin fusion protein containing the extracellular region of hu-
man c-Mpl (MPL-IgG). One of these benzodiazepinones,
TM41, stimulated the proliferation of UT-7/TPO cells. In ad-
dition, it activated STAT5 in a manner similar to that of
TPO. These results show that TM41 mimics the e¡ect of
TPO via c-Mpl.
2. Materials and methods
2.1. Hematopoietic growth factor and reagents
Benzodiazepinones which we termed TM compounds were synthe-
sized by Hokuriku Seiyaku Co. (Fukui, Japan). Recombinant human
TPO was obtained from RpD Systems (Minneapolis, MN, USA).
Recombinant human GM-CSF was obtained from Genzyme (Cam-
bridge, MA, USA). 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium (WST-1) and 1-methoxy-5-methylphenazi-
nium methylsulfate (1-methoxy PMS) were obtained from Wako
(Tokyo, Japan).
2.2. Competition binding assay
MPL-IgG is the soluble form of human c-Mpl containing the ex-
tracellular ligand binding domain of c-Mpl and the human immuno-
globulin Fc region. It was prepared as described previously [29].
Brie£y, 96-well plates were coated with MPL-IgG at 10 ng/well in
phosphate-bu¡ered saline (PBS), and incubated at 4‡C overnight.
The wells were then blocked with PBS containing 1% bovine serum
albumin (BSA). Mixtures of TM compounds at concentrations rang-
ing from 3 WM to 1 mM and the constant concentration of 2 ng/ml
TPO were added and incubated in MPL-IgG immobilized wells. After
incubation for 1 h, the wells were washed and the remaining bound
TPO was detected by goat anti-human TPO antibody (RpD Systems)
and then donkey anti-goat IgG conjugated to horseradish peroxidase
(HRP; Chemicon International, Temecula, CA, USA). The absorb-
ance was measured at a wavelength of 450 nm using a microplate
reader (model M-Vmax; Molecular Device, Menlo Oaks, CA, USA).
2.3. Cells and culture
The human leukemia cell lines UT-7 and UT-7/TPO were kindly
provided by Dr. N. Komatsu (Jichi Medical School, Tochigi, Japan)
[31,33]. UT-7 cells were maintained in Iscove’s modi¢ed Dulbecco’s
medium (IMDM; Gibco, Rockville, MD, USA) containing 10% fetal
calf serum (FCS; Intergen, Purchase, NY, USA) and 0.5 ng/ml GM-
CSF. UT-7/TPO cells were maintained in IMDM containing 10%
FCS and 1 ng/ml TPO.
2.4. WST-1 assay for cell proliferation
UT-7 cells and UT-7/TPO cells were starved of growth factor for 24
h. These cells were resuspended at a density of 2U104 cells/0.1 ml
IMDM containing 10% FCS and incubated in 96-well plates in the
absence or presence of various concentrations of TM compounds,
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TPO or GM-CSF for 3 days. 10 Wl of 1 mM WST-1 and 0.2 mM 1-
methoxy PMS were added to each well, and the plates were incubated
for 4 h. The absorbance was measured at a wavelength of 450 nm
using a microplate reader.
2.5. Electrophoretic mobility shift assay (EMSA)
UT-7 cells and UT-7/TPO cells were starved of growth factor for 24
h. These cells were incubated with TM compounds, TPO or GM-CSF
for 15 min at 37‡C. Nuclear extracts were prepared as described by
Sadowski et al. [34]. The STAT5 binding site of the bovine L-casein
promoter (5P-AGATTTCTAGGAATTCAATCC-3P) was used as a
probe [35]. The probe was end-labeled with [Q-32P]ATP with T4 poly-
nucleotide kinase and used about 1 ng (about 1U105 cpm) per reac-
tion. Extracts (from 2.5U105 cells/point) were incubated in 20 Wl of
reaction mixture containing 10 mM HEPES, pH 7.9, 5% glycerol, 30
mM NaCl, 0.1% NP-40, 1 mg/ml BSA, 1 mM EDTA and 0.5 mg/ml
of salmon sperm DNA at room temperature for 30 min. For the
competition experiment, 100-fold excess of unlabeled probe was added
to the reaction mixture. For supershift experiment, 2 Wg of anti-
STAT5 antibody which reacted with STAT5a and STAT5b (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was added to the reac-
tion mixture. Samples were loaded onto 5% polyacrylamide gels and
then analyzed with a bioimaging analyzer BAS2000 (Fujix, Tokyo,
Japan).
3. Results
3.1. TM compounds inhibit the binding of TPO to the
MPL-IgG
MPL-IgG was utilized in a competition binding assay to
screen many compounds that inhibited the binding of TPO
to c-Mpl. Most compounds, represented by TM3, did not
inhibit the TPO binding to MPL-IgG (Fig. 1A), but several
compounds such as TM4 and TM41 were identi¢ed as dose-
dependent inhibitors of the binding of TPO to MPL-IgG (Fig.
1B). These compounds, with a benzodiazepinone structure
with an amino residue at position 1, are shown in Fig. 1B.
3.2. TM41 stimulates the proliferation of UT-7/TPO cells
To determine whether TM4 and TM41 have the same bio-
logical activity as TPO, we tested these compounds in a cell
proliferation bioassay. UT-7/TPO is a useful cell line for the
study of the action of TPO, because this cell line has a mor-
phologically mature megakaryocytic character and grows in
response to TPO [33]. TM4 did not stimulate the proliferation
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Fig. 1. Competition binding assays and chemical structure of TM compounds. A: 96-well plates were coated with MPL-IgG. TM compounds
(3 WM^1 mM) and 2 ng/ml TPO were added and incubated in MPL-IgG immobilized wells. The wells were then washed and the remaining
bound TPO was detected by goat anti-TPO antibody and then donkey anti-goat IgG conjugated to HRP. The absorbance was measured. The
values shown are the means of duplicate determination. B: Structures of TM compounds. TM3, ( þ )-1,3-dihydro-1-(4-hydroxybutyl)-3-(1H-in-
dol-3-ylmethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one; TM4, ( þ )-1-(4-aminobutyl)-1,3-dihydro-3-(1H-indol-3-ylmethyl)-5-phenyl-2H-1,4-benzo-
diazepin-2-one; TM41, ( þ )-1-(4-aminobutyl)-1,3-dihydro-3-[(4-hydroxyphenyl)methyl)-5-phenyl-2H-1,4-benzodiazepin-2-one.
Fig. 2. Proliferative response of UT-7 cells and UT-7/TPO cells to
TM41. UT-7 cells and UT-7/TPO cells were deprived of growth fac-
tor for 24 h and then plated at a density of 2U104 cells/well in
IMDM containing 10% FCS and incubated in the absence or pres-
ence of TM41, TPO or GM-CSF. After 3 days, the absorbance was
measured by the WST-1 assay described in Section 2. The values
shown are the means of triplicate determinations.
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Fig. 3. Activation of STAT5 in UT-7/TPO cells to TM41. A:) UT-7
cells (left) and UT-7/TPO cells (right) were deprived of growth fac-
tor for 24 h and then incubated with TM41, TPO or GM-CSF at
the indicated concentration for 15 min. Nuclear extracts were pre-
pared. An EMSA was performed on the extracts using a 32P-labeled
oligonucleotide containing L-casein promoter. 100-fold excess of un-
labelled probe was added as a competitor. S indicates the shifted
complex, and NS is a non-speci¢c band. B: Nuclear extracts from
UT-7/TPO cells treated with TM41 (100 WM), TPO (10 ng/ml) or
GM-CSF (10 ng/ml) for 15 min were analyzed by an EMSA in the
presence of anti-STAT5 antibody. S indicates the shifted complex.
SS indicates the supershifted complex.
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of UT-7/TPO cells and UT-7 cells (data not shown). TM41
stimulated the proliferation of UT-7/TPO cells, although it
did not stimulate the proliferation of parental UT-7 cells,
which do not respond to TPO (Fig. 2). This indicates that
although the biological potential of TM41 is weaker than
that of rhTPO, it may act as an agonist for c-Mpl.
3.3. TM41 stimulates the activation of STAT5 in
TPO-dependent cells
TPO induces the tyrosine phosphorylation of several pro-
teins, including c-Mpl, Shc, JAK2, STAT5 and so on [16^27].
GM-CSF, EPO and IL-3 also activate JAK2 and STAT5
[10,14]. Because STAT5 is an early and important substrate
of activated JAK2 via c-Mpl, we investigated whether TM41
can induce the activation of STAT5 in UT-7/TPO cells by
EMSA. UT-7 cells and UT-7/TPO cells express JAK2 and
STAT5 [24,33,38]. The EMSA was performed using bovine
L-casein promoter as a probe for STAT5 [35]. Nuclear ex-
tracts prepared from TM41-, TPO- or GM-CSF-treated UT-
7/TPO cells dose-dependently possessed DNA binding activity
(Fig. 3A). The density of the shifted complex derived from
TM41-, hTPO- or hGM-CSF-treated UT-7/TPO cells paral-
leled the growth stimulation activity against UT-7/TPO cells.
The formation of these complexes was completely inhibited by
a 100-fold excess of unlabeled probe, indicating that the pro-
teins bound speci¢cally to the probe. Although the nuclear
extracts prepared from GM-CSF-treated UT-7 cells also pos-
sessed the same activity, those of TM41- or TPO-treated UT-7
cells did not possess the activity (Fig. 3A).
To further examine these results, a supershift experiment
was performed with an anti-STAT5 antibody. The supershift
experiment showed that the presence of anti-STAT5 antibody
apparently altered the mobility of the DNA-protein binding
complex, indicating the presence of an immunologic STAT5
in TM41-, TPO- or GM-CSF- treated extracts of UT-7/TPO
cells (Fig. 3B).
4. Discussion
TPO will be useful for the treatment of thrombocytopenia,
but it has signi¢cant drawbacks including oral unavailability
and potential immunogenicity. The function of TPO and EPO
via receptors can be mimicked by smaller peptides which were
isolated from random peptide libraries on ¢lamentous phage
[28^30]. However, such mimetic peptides may not have the
same e¡ects when they are orally administered. Non-peptide
agonistic ligands for the cholecystokinin and somatostatin re-
ceptors have been obtained [36,37]. The most prominent bio-
active forms of these hormones are 8 and 14 amino acids,
respectively. There has been no report, to our knowledge,
that a non-peptide compound mimics a cytokine or growth
factor which is a large polypeptide hormone. In this study, we
tried to ¢nd a non-peptide compound which has physiological
activities similar to those of TPO.
TPO and TPO-mimetic peptides bind to MPL-IgG [1,29].
We used MPL-IgG as a source to search for a non-peptide
compound which can mimic an activity of TPO via c-Mpl.
Several synthetic compounds were identi¢ed that inhibited the
binding of TPO to MPL-IgG in a concentration-dependent
manner. Two compounds, TM4 and TM41, were investigated.
They exhibit a close structural relationship (Fig. 1B); they
each have benzodiazepinone with amino residues at position
1. We next checked the e¡ect of these compounds on the
proliferation of UT-7/TPO cells. TM41, but not TM4, stimu-
lated the proliferation of UT-7/TPO cells. When UT-7/TPO
cells were cultured with TM4 at 10^100 WM in the presence of
1 ng/ml hTPO, the proliferation of the cells was dose-depend-
ently inhibited by TM4 (data not shown). TM4 may be an
antagonist for c-Mpl.
TPO induces the tyrosine phosphorylation of JAK2 and
TYK2 and the activation of STAT1, STAT3 and STAT5 in
several cell lines, including mouse megakaryocytes and human
platelets [16^27]. Activation of STAT1 and STAT3 was not
detected in UT-7/TPO cells by TPO [33]. We thus examined
whether TM41 also induced the activation of STAT5. TM41
induced the activation of STAT5 in UT7/TPO cells. These
results indicate that a low molecular weight compound can
attain the a⁄nity of c-Mpl binding and potency of c-Mpl
activation possessed by TPO.
TPO shows homology to the primary amino acid sequences
of EPO [1,2]. The amino acid sequence of c-Mpl is highly
conserved to the common Lc receptor of GM-CSF, IL-3
and IL-5, and EPO receptors [9]. The question remains
whether TM41 activates other cytokine receptors. UT-7 cells
grow dependent not only on GM-CSF but also on EPO and
IL-3, and their maximal proliferation activity is the same as
that of GM-CSF [31]. Since TM41 did not stimulate the pro-
liferation and the activation of STAT5 in UT-7 cells, the
target of TM41 seems to be speci¢c for c-Mpl.
c-Mpl seems to be activated as a homodimer, similar to the
receptors for growth hormone, GM-CSF and EPO [39^42].
The activation of c-Mpl by TM41 could be explained in the
following two ways: (i) TM41 causes conformational changes
of receptor which induce receptor-receptor interactions; or (ii)
TM41 binds to two receptor molecules in a bivalent manner,
and this mimics receptor homodimerization. The actual mode
of action may be resolved by three-dimensional nuclear mag-
netic resonance or X-ray crystal analysis of the compound-
receptor complex.
In conclusion, TM41 stimulates the proliferation of human
megakaryocytic cell lines. To our knowledge, this is the ¢rst
demonstration of the activation of cytokine receptor by a low
molecular weight compound. TM41 is useful in vitro as a
unique tool for investigating the biological role of TPO via
c-Mpl. Moreover, the use of TM41 could lead to the design
and discovery of more potent low molecular weight drugs that
mimic the therapeutically important protein TPO.
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